NYSE:ZTSPharmaceuticals
A Look At Zoetis (ZTS) Valuation After Librela Setbacks And Guidance Cut
Conference spotlight and recent sentiment shift
Zoetis (ZTS) is back in focus as Senior VP of Global Biologics R&D, Mahesh Kumar, presents at the World Vaccine Congress Washington 2026. The event is drawing attention to the company after a stretch of weaker investor sentiment.
Recent setbacks around its osteoarthritis drug Librela, increased competition, negative social media coverage, and lowered annual guidance have weighed on the stock. This comes despite Zoetis previously exceeding...